Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

被引：0

作者：

Lombardi, G. ^{[1
]}

Del Bianco, P. ^{[2
]}

Brandes, A. A. ^{[3
]}

Eoli, M. ^{[4
]}

Ruda, R. ^{[5
,6
]}

Ibrahim, T. ^{[7
]}

Lolli, I. R. ^{[8
]}

Pace, A. ^{[9
]}

Daniele, B. ^{[10
]}

Pasqualetti, F. ^{[11
]}

Rizzato, S. ^{[12
]}

Bergo, E. ^{[1
]}

Caccese, M. ^{[1
]}

Padovan, M. ^{[1
]}

Soffietti, R. ^{[5
,6
]}

De Salvo, G. L. ^{[2
]}

Zagonel, V. ^{[1
]}

机构：

[1] IOV IRCCS, Veneto Inst Oncol, Dept Oncol, Oncol 1, Padua, Italy

[2] IOV IRCCS, Veneto Inst Oncol, Clin Res Unit, Padua, Italy

[3] AUSL IRCCS Sci Neurol, Dept Med Oncol, Bologna, Italy

[4] Besta Inst, Mol Neurooncol Unit, Milan, Italy

[5] Univ Turin, Dept Neurooncol, Turin, Italy

[6] City Hlth & Sci Hosp, Turin, Italy

[7] IRST Ist Sci Romagnolo Studio & Cura Tumori IRCCS, Med Oncol Unit, Meldola, Forli Cesena, Italy

[8] IRCCS Saverio de Bellis, Med Oncol Unit, Bari, Italy

[9] Regina Elena Canc Inst IRCCS, Neuroncol Unit, Rome, Italy

[10] AOG Rummo, Med Oncol Unit, Benevento, Italy

[11] Azienda Osped Univ, Radiotherapy Unit, Pisa, Italy

[12] Azienda Sanit Univ Integrata Udine, Dept Oncol, Udine, Italy

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

394O

引用

页数：1

共 50 条

[21] Impact of bevacizumab added to temozolomide-chemoradiation on time to health-related quality of life deterioration in unresectable glioblastoma: Results of a phase II randomized clinical trial [J].

Bonnetain, Franck ;

Dabakuyo, Tienhan Sandrine ;

Pozet, Astrid ;

Feuvret, Loic ;

Taillandier, Luc ;

Frappaz, Didier ;

Taillia, Herve ;

Schott, Roland ;

Honnorat, Jerome ;

Fabbro, Michel ;

Tennevet, Isabelle ;

Ghiringhelli, Francois ;

Campello, Chantal ;

Castera, Daniel ;

Frenay, Marc ;

Dalban, Cecile ;

Skrzypski, Jeremy ;

Chinot, Olivier L. ;

Chauffert, Bruno ;

Anota, Amelie .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[22] UPDATED RESULTS OF REGOMA: A RANDOMIZED, MULTICENTER, CONTROLLED OPEN-LABEL PHASE II CLINICAL TRIAL EVALUATING REGORAFENIB IN RELAPSED GLIOBLASTOMA <GBM> PATIENTS <PTS> [J].

Lombardi, G. ;

de Salvo, G. ;

Ruda, R. ;

Franceschi, E. ;

Eoli, M. ;

Faedi, M. ;

Pace, A. ;

Lolli, I. ;

Rizzato, S. ;

Germano, D. ;

Pasqualetti, F. ;

Farina, M. ;

Magni, G. ;

Bellu, L. ;

Caccese, M. ;

Pambuku, A. ;

Bergo, E. ;

Indraccolo, S. ;

Gardiman, M. ;

Soffietti, R. ;

Zagonel, V. .

NEURO-ONCOLOGY, 2018, 20 :219-219

[23] Prospective Evaluation of Health-Related Quality of Life and Neurocognitive Status in Patients With Glioblastoma Multiforme Treated on a Phase II Trial of Hypofractionated Radiation Therapy With Temozolomide [J].

Reddy, K. ;

Gaspar, L. E. ;

Kavanagh, B. D. ;

Waziri, A. ;

Chen, C. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03) :S269-S269

[24] Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma [J].

Field, Kathryn M. ;

King, Madeleine T. ;

Simes, John ;

Espinoza, David ;

Barnes, Elizabeth H. ;

Sawkins, Kate ;

Rosenthal, Mark A. ;

Cher, Lawrence ;

Hovey, Elizabeth ;

Wheeler, Helen ;

Nowak, Anna K. .

JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (03) :623-631

[25] Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma [J].

Kathryn M. Field ;

Madeleine T. King ;

John Simes ;

David Espinoza ;

Elizabeth H. Barnes ;

Kate Sawkins ;

Mark A. Rosenthal ;

Lawrence Cher ;

Elizabeth Hovey ;

Helen Wheeler ;

Anna K. Nowak .

Journal of Neuro-Oncology, 2017, 133 :623-631

[26] EFFECTS OF TUMOR TREATING FIELDS ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED GLIOBLASTOMA: AN EXPLORATORY ANALYSIS OF THE EF-14 RANDOMIZED PHASE III TRIAL [J].

Walbert, T. ;

Lavy-Shahaf, G. .

NEURO-ONCOLOGY, 2018, 20 :242-242

[27] HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA [J].

Taphoorn, Martin J. B. ;

Henriksson, Roger ;

Bottomley, Andrew ;

Cloughesy, Timothy ;

Wick, Wolfgang ;

Mason, Warren ;

Saran, Frank ;

Nishikawa, Ryo ;

Ravelo, Arliene ;

Hilton, Magalie ;

Chinot, Olivier L. .

NEURO-ONCOLOGY, 2013, 15 :232-232

[28] EFFECTS OF TUMOR TREATING FIELDS ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN NEWLY DIAGNOSED GLIOBLASTOMA: AN EXPLORATORY ANALYSIS OF THE EF-14 RANDOMIZED PHASE III TRIAL [J].

Walbert, Tobias ;

Lavy-Shahaf, Gitit .

NEURO-ONCOLOGY, 2018, 20 :214-214

[29] Effects of Alefacept on Health-Related Quality of Life in Patients with PsoriasisResults from a Randomized, Placebo-Controlled Phase II Trial [J].

Charles N. Ellis ;

Margaret M. Mordin ;

Ellen Y. Adler .

American Journal of Clinical Dermatology, 2003, 4 :131-139

[30] Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin [J].

Diana Rofail ;

Antoine Regnault ;

Stéphanie le Scouiller ;

Carmen Galani Berardo ;

Daniel Umbricht ;

Ray Fitzpatrick .

Quality of Life Research, 2016, 25 :201-211

← 1 2 3 4 5 →